Plain-English translation of NCT06756152 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
After a stem cell transplant, the new immune cells can sometimes attack the patient's body—a serious complication called graft-versus-host disease. This trial tests whether cyclophosphamide combined with three other medications (abatacept, vedolizumab, and ruxolitinib) can prevent this complication in children and young adults with blood cancers. The researchers want to see if this four-drug combination is both safe and effective.
Graft-versus-host disease is one of the biggest dangers after a stem cell transplant and can cause severe illness or death. This study exists to see if adding three newer medications to a standard preventive drug can reduce how often and how badly this complication occurs.
You likely qualify if…
You likely don't qualify if…
You would receive chemotherapy to prepare your body for the transplant, then the new stem cells. Starting a few days after the transplant, you would take ruxolitinib by mouth twice daily for up to 3 months. You would also receive cyclophosphamide by injection on days 3 and 4 after transplant, followed by four doses of abatacept and vedolizumab on specific days. You would have frequent blood tests and clinic visits to monitor your health for up to 3 years after the transplant.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
Russia